← All trials
NCT05359224
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2022
- Primary completion
- Jul 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- May 3, 2022
- Last posted
- Jul 15, 2022
- Enrollment
- 406
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yonsei UniversityLead sponsor
- Catholic Kwandong UniversityCollaborator
- Yonsei UniversityCollaborator
- Yonsei UniversityCollaborator
- Yonsei UniversityReponsible party - principal investigator
- Yonsei UniversityStudy director
- Catholic University of KoreaCollaborator
- Ewha Womans UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.